Etoricoxib in Patients With Parkinsonian Disease

Ihab Elsayed Hassan

Status and phase: Begins enrollment in 4 months; Phase 2

Conditions: Parkinson Disease

Treatments: Drug: Etoricoxib; Drug: L-dopa

Study type: Interventional

Funder types: Other

Identifiers

NCT07370532

98658

Details and patient eligibility

About

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE).

Enrollment: 60 estimated patients

Sex: All

Ages: 50 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years.
• Both male and female will be included.
• Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion criteria

• Breast feeding
• Patients with significant liver and kidney function abnormalities.
• Alcohol and / or drug abusers.
• Patients with known allergy to the study medications
• Pregnant women and women with planned pregnancy.
• Patients who are currently using other anti-inflammatory drugs.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups

Control group

Active Comparator group

Description:

(levo-dopa group, n =30) who will receive levo-dopa/carbidopa (125/12.5) mg three times daily for 6 months.

Treatment:

Drug: L-dopa

Etoricoxib group

Active Comparator group

Description:

will receive levo-dopa/carbidopa (125/12.5) mg three times daily plus Etoricoxib 90 mg once daily

Treatment:

Drug: L-dopa

Drug: Etoricoxib